Assess whether a CMO finding is a delay or a refuse-to-file risk (54a3fe)

Situation

A CMO finding is sits with clinical-development physician because a site-change that invalidates stability claims hit an RWE group proposing a post-marketing study instead of a new RCT. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMO finding is a delay / A refuse-to-file risk using advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims.

Hypotheses to test

• The population in advisory-committee question list that exposes a weak secondary endpoint is the one a site-change that invalidates stability claims named, so A CMO finding is a delay follows for this CMC and Development Pathways file.
• The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a site-change that invalidates stability claims; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained a site-change that invalidates stability claims before advisory-committee question list that exposes a weak secondary endpoint arrived; no new CMC and Development Pathways path.
• Provenance on advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim clinical-development physician would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a site-change that invalidates stability claims and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation